| Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes. | |
| | |
MedLine Citation:
|
PMID: 9857884 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The purpose of this study was to compare the outcome of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (MI) when performed with or without the platelet glycoprotein IIb/IIIa antibody, abciximab. BACKGROUND: Abciximab improves the outcome of angioplasty but the effect of abciximab in primary angioplasty has not been investigated. METHODS: Data were collected from a computerized database. Follow-up was by telephone or review of outpatient or hospital readmission records. RESULTS: A total of 182 consecutive patients were included; 103 received abciximab and 79 did not. The procedural success rate was 95% in the two groups. At 30-day follow-up, the composite event rate of unstable angina, reinfarction, target vessel revascularization and death from all causes was 13.5% in the group of patients who did not receive abciximab, 4% (p < 0.05) in the abciximab group and 2.4% (p < 0.05) in the subgroup of patients (n = 87) who completed the 12-h abciximab infusion. At the end of follow-up (mean 7+/-4 months), the composite event rate was 32.4%, 17% (p < 0.05) and 13.1% (p < 0.01) in these three categories respectively. Abciximab bolus followed by a 12-h infusion was an independent predictor of event-free survival, in a Cox proportional hazards model (relative risk 0.49; 95% confidence interval 0.24 to 0.99; p < 0.05). CONCLUSIONS: Abciximab given at the time of primary angioplasty may improve the short- and medium-term outcome of patients with acute MI, especially when a 12-h infusion is completed. |
| | |
Authors:
|
R R Azar; R G McKay; P D Thompson; J A Hirst; J F Mitchell; D B Fram; D D Waters; F J Kiernan |
Related Documents
:
|
9266794 - Comparison of 6f with 7f and 8f guiding catheters for elective coronary angioplasty: re... 2529974 - Percutaneous coronary angioplasty of large venous graft using peripheral dilatation cat... 8482024 - Evaluation of myocardial perfusion and function by technetium-99m methoxy isobutyl ison... 11113044 - Percutaneous coronary intervention in the current era compared with 1985-1986: the nati... 1588944 - Occurrence of oxidative stress during myocardial reperfusion. 11959384 - Absence of change of signal-averaged electrocardiogram identifies patients with ventric... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 32 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 1998 Dec |
Date Detail:
|
Created Date: 1999-01-05 Completed Date: 1999-01-05 Revised Date: 2005-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1996-2002 Citation Subset: AIM; IM |
Affiliation:
|
Division of Cardiology, Hartford Hospital and the University of Connecticut School of Medicine, USA. razar@bidmc.harvard.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angioplasty, Transluminal, Percutaneous Coronary* Antibodies, Monoclonal / therapeutic use* Female Humans Immunoglobulin Fab Fragments / therapeutic use* Male Middle Aged Multivariate Analysis Myocardial Infarction / mortality, therapy* Platelet Aggregation Inhibitors / therapeutic use* Proportional Hazards Models Survival Analysis Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; 143653-53-6/abciximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparative prognostic value of automatic quantitative analysis versus semiquantitative visual analy...
Next Document: Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the P...